ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

FENC vs JNJ // RSI-14 & 200D SMA MOMENTUM

Fennec Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: FENC 0 — JNJ 9
▲ RSI-14 & 200D SMA MOMENTUM LEADER: JNJ
rsi-technicals
62.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FENC VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC FENC JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 67.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -25.90% 25.50% -51.40 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield -3.25% 2.97% -6.22 JNJ /fcf-yield <GO>
Operating Margin -14.10% 34.70% -48.80 JNJ /operating-margins <GO>
Net Profit Margin -60.00% 28.50% -88.50 JNJ /net-margins <GO>
Revenue Growth (YoY) -6.10% 6.00% -12.10 JNJ /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.31 5.59 -2.28 JNJ /balance-sheet <GO>
Piotroski F-Score Quality 2/9 8/9 -6.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 55.0 62.1 -7.10 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $383.6M $662.49B -$662.11B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR FENC REV JNJ REV FENC GROSS % JNJ GROSS % FENC FCF JNJ FCF
FY 2025 $44.6M $94.19B — 67.9% -$12.5M $19.70B
FY 2024 $47.5M $88.82B — 69.1% $27.0M $19.84B
FY 2023 $21.3M $85.16B — — -$17.1M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FENC // BETA —
JNJ // BETA 1.08